141699-58-3

Basic information

• Product Name: 1-(Tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine
• Synonyms: 1-(Tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine;1-(tert-butoxycarbonyl)azetidine-3-yl-methanesulfonate;N-Boc-3-methanesulfonyloxyazetidine;1-Boc-3-methanesulfonyloxy-azetidine;3-((Methylsulfonyl)oxy)azetidine-1-carboxylic acid tert-butyl ester;3-[(Methanesulfonyl)oxy]azetidine-1-carboxylic acid tert-butyl ester;tert-Butyl 3-[(methylsulfonyl)oxy]azetane-1-carboxylate;tert-Butyl 3-[(methylsulfonyl)oxy]-1-azetidinecarboxylate
• CAS NO: 141699-58-3
• Molecular Formula: C₉H₁₇NO₅S
• Molecular Weight: 251.29998
• Product Categories: CMLLYL
• Mol File: 141699-58-3.mol
• Article Data: 79

Chemical Properties

• Melting Point: 69 °C
• Boiling Point: 378.534°C at 760 mmHg
• Flash Point: 182.731°C
• Appearance: /
• Density: 1.283g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -4.18±0.40(Predicted)
• CAS DataBase Reference: 1-(Tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine(141699-58-3)
• EPA Substance Registry System: 1-(Tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine(141699-58-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• HazardClass: IRRITANT
• Hazardous Substances Data: 141699-58-3(Hazardous Substances Data)

Usage

General Description

1-(Tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine is a chemical compound that is an azetidine derivative with a tert-butoxycarbonyl (Boc) protecting group on the nitrogen atom and a methanesulfonyloxy group on the carbon atom. It is commonly used as a reagent in organic synthesis, particularly in the formation of amine derivatives. The Boc protecting group provides stability to the nitrogen atom, allowing for selective manipulations of other functional groups in the molecule, while the methanesulfonyloxy group serves as a leaving group in nucleophilic substitution reactions. 1-(Tert-butoxycarbonyl)-3-(methanesulfonyloxy)azetidine is important in the development of pharmaceuticals, agrochemicals, and other fine chemicals due to its versatile reactivity and ability to facilitate complex synthetic transformations.

InChI:InChI=1/C9H17NO5S/c1-9(2,3)14-8(11)10-5-7(6-10)15-16(4,12)13/h7H,5-6H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 36476-89-8 azetidin-3-yl methanesulfonate hydrochloride 
• 124-63-0 methanesulfonyl chloride 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 67160-19-4 3-methanesulfonyloxy-azetidine 

Downstream Products

• 254454-54-1 tert-butyl-3-iodoazetidine-1-carboxylate 
• 142253-54-1 tert-butyl 3-cyanoazetidine-1-carboxylate 
• 325775-44-8 tert-butyl 3-(aminomethyl)azetidine-1-carboxylate 
• 1028286-25-0 3-(benzoylamino-methyl)-azetidine-1-carboxylic acid tert-butyl ester 
• 1026942-02-8 3-(benzenesulfonylamino-methyl)-azetidine-1-carboxylic acid tert-butyl ester 
• 1026576-25-9 3-[(cyclohexanecarbonyl-amino)-methyl]-azetidine-1-carboxylic acid tert-butyl ester 
• 877399-34-3 tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)azetidine-1-carboxylate 
• 1227622-77-6 3-[2-(3-chloro-benzyloxy)-5-fluoro-phenoxy]-azetidine-1-carboxylic acid tert-butyl ester 
• 960492-52-8 tert-butyl 3-(2-(trifluoromethyl)phenoxy)-azetidine-1-carboxylate 
• 1332300-75-0 tert-butyl 3-(2-(trifluoromethoxy)phenoxy)azetidine-1-carboxylate 
• 954236-10-3 tert-butyl 3-(quinolin-8-yloxy)azetidine-1-carboxylate 
• 1268486-04-9 C₂₀H₂₃NO₄ 
• 1268486-06-1 C₂₀H₂₁F₂NO₄ 
• 1268486-05-0 C₂₀H₂₂FNO₄ 

Relevant articles and documents

PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer 5 or a metabolic disease.

RET inhibitor and pharmaceutical composition and application thereof

The invention belongs to the field of medicines, and relates to an RET inhibitor and a pharmaceutical composition and application thereof. Specifically, the invention relates to a compound as shown in a formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula (I). The invention also relates to pharmaceutical compositions comprising the compounds, and uses of the compounds and pharmaceutical compositions thereof in the preparation of a medicine which is especially used for the treatment and prevention of RET-related diseases and disorders, including cancers, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.

RET Inhibitor. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to RET inhibitor, a pharmaceutical composition and application thereof. , The present invention relates to a compound represented by formula (I), a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug thereof, I, and a pharmaceutical composition thereof in the manufacture of a medicament, in particular for the treatment and prophylaxis of diseases and disorders associated and RET.